Free Trial
NASDAQ:BCTX

BriaCell Therapeutics 10/25/2023 Earnings Report

BriaCell Therapeutics logo
$4.29 -0.19 (-4.24%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$4.22 -0.07 (-1.61%)
As of 04/17/2025 06:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BriaCell Therapeutics EPS Results

Actual EPS
-$2.25
Consensus EPS
-$6.00
Beat/Miss
Beat by +$3.75
One Year Ago EPS
N/A

BriaCell Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BriaCell Therapeutics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

BriaCell Therapeutics' next earnings date is estimated for Friday, June 13, 2025, based on past reporting schedules.

Conference Call Resources

BriaCell Therapeutics Earnings Headlines

BriaCell announces survival data from its Phase 2 study of Bria-IMT
The first casualty of the 2025 trade war
The headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim Plaehn reveals how the 2025 trade war is quietly eroding dividend income — and which U.S.-focused stocks are still raising payouts.
See More BriaCell Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BriaCell Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BriaCell Therapeutics and other key companies, straight to your email.

About BriaCell Therapeutics

BriaCell Therapeutics (NASDAQ:BCTX), a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

View BriaCell Therapeutics Profile

More Earnings Resources from MarketBeat